Compounds > amedin
Page last updated: 2024-11-08

amedin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

amedin: acetylcholine antagonist; RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID168386
CHEMBL ID1619633
MeSH IDM0066068

Synonyms (27)

Synonym
MLS000068648 ,
amedin
cyclohexyl-hydroxy-phenyl-acetic acid 2-dimethylamino-ethyl ester
smr000012218
2-(dimethylamino)ethyl cyclohexyl(hydroxy)phenylacetate
STK067602
AKOS003658236
NCGC00072871-02
dimethylaminoethylphenylcyclohexyl glycolic acid
25520-98-3
dimethylamainoethyl 2-cyclohexyl-2-hydroxy-2-phenyl acetate
tvbomp5fuc ,
unii-tvbomp5fuc
AKOS022081914
AB00479718-09
2-cyclohexyl-2-hydroxy-2-phenyl-acetic acid 2-(dimethylamino)ethyl ester;hydrochloride
2-cyclohexyl-2-hydroxy-2-phenylacetic acid 2-(dimethylamino)ethyl ester;hydrochloride
bdbm37618
2-(dimethylamino)ethyl 2-cyclohexyl-2-oxidanyl-2-phenyl-ethanoate;hydrochloride
cid_3083979
CHEMBL1619633
dimethylaminoethyl-2-cyclohexyl-2-hydroxy-2-phenylacetate
.alpha.-cyclohexyl-.alpha.-hydroxy-, 2-(dimethylamino)ethyl ester, benzeneacetic acid
.alpha.-phenyl-, 2-(dimethylamino)ethyl ester, cyclohexaneglycolic acid
NCGC00072871-03
2-(dimethylamino)ethyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
DTXSID10948424
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.74 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index48.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
haloperidol
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.		2.0210aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol		antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
trihexyphenidyl
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.		2.0210amine
cyclopentane
Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.		2.0210cycloalkane;
cyclopentanes;
volatile organic compound		non-polar solvent
methoctramine
methoctramine: structure given in first source. methoctramine : A tetramine that is N,N'-bis(6-aminohexyl)octane-1,8-diamine where the primary amino groups both carry 2-methoxybenzyl substituents.. methoctramine tetrahydrochloride : A hydrochloride obtained by combining methoctramine with four molar equivalents of hydrochloric acid.		2.0210hydrochloridemuscarinic antagonist
piperidines
Piperidines: A family of hexahydropyridines.		2.0210
ConditionIndicatedRelationship StrengthStudiesTrials
Anochlesia
[description not available]		02.0210
Symptom Cluster
[description not available]		02.3820
Syndrome
A characteristic symptom complex.		02.3820
Basal Ganglia Diseases
Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.		01.9510
Cerebral Palsy, Athetoid
[description not available]		01.9510
Childhood Torsion Disease
[description not available]		01.9510
Inner Ear Disease
[description not available]		01.9510
Dyskinesia Syndromes
[description not available]		01.9510
Abnormal Deep Tendon Reflex
[description not available]		01.9510
Cerebral Palsy
A heterogeneous group of nonprogressive motor disorders caused by chronic brain injuries that originate in the prenatal period, perinatal period, or first few years of life. The four major subtypes are spastic, athetoid, ataxic, and mixed cerebral palsy, with spastic forms being the most common. The motor disorder may range from difficulties with fine motor control to severe spasticity (see MUSCLE SPASTICITY) in all limbs. Spastic diplegia (Little disease) is the most common subtype, and is characterized by spasticity that is more prominent in the legs than in the arms. Pathologically, this condition may be associated with LEUKOMALACIA, PERIVENTRICULAR. (From Dev Med Child Neurol 1998 Aug;40(8):520-7)		01.9510
Labyrinth Diseases
Pathological processes of the inner ear (LABYRINTH) which contains the essential apparatus of hearing (COCHLEA) and balance (SEMICIRCULAR CANALS).		01.9510
Movement Disorders
Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.		06.9510
Reflex, Abnormal
An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.		01.9510